An interventional study of HGAS and HGS in Malignant Biliary Obstruction and Malignant Biliary Stricture, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
The purpose of this study is to compare the efficacy and safety between EUS-HGAS and EUS-HGS. We hypothesized that EUS-HGAS provides lower recurrent biliary obstruction (RBO) rate but with a comparable safety profile to EUS-HGS.
456 studies on the registry are indexed under Constriction, Pathologic; 109 are open to participants now.
This study's planned enrollment of 88 is above the median of 72 across 295 interventional studies indexed under Constriction, Pathologic.
Browse Constriction, Pathologic studies →National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endoscopic ultrasound guided hepaticogastrostomy
Device: HGS
Endoscopic ultrasound guided hepaticogastrostomy with antegrade stenting through the major papilla
Device: HGAS
Endoscopic ultrasound guided hepaticogastrostomy with antegrade stenting
Endoscopic ultrasound guided hepaticogastromy
Recurrent biliary obstruction (RBO) rate
the proportion of participants experiencing RBO, defined by cholangitis, jaundice or findings of images, from index day of EUS-BD to the date of last follow-up
Time frame: From enrollment to the end of follow-up up to 12 months
Time to Recurrent Biliary Obstruction
Time frame: From date of enrollment until the date of first documented recurrent biliary obstruction, date of death from any cause or date of last follow-up, whichever came first, assessed up to 12 months
Tract dilation success
tract dilation was regarded as successful when the maximum diameter portion of the first dilator into the bile duct
Time frame: From the start of the EUS-BD to completion or failure of dilation, assessed on the day of the drainage procedure
Final procedure success
a successful deployment of a stent in the intended location
Time frame: From the start of the EUS-BD to completion or failure of stent deployment, assessed on the day of the drainage procedure
Procedural duration
Time frame: The time elapsed between puncture of the intrahepatic duct and completion of deployment of stent, assessed on the day of the drainage procedure.
Clinical success
Time frame: a decrease in bilirubin within 14 days to < 50 % of levels before EUS-BD
Adverse events
bleeding (hematemesis and/or melena or hemoglobin drop over 2g/dL, needed blood transfusion, endoscopic hemostasis, radiological intervention or surgery), pancreatitis, cholangitis, peritonitis, and perforation, in accordance with the American Society for GI Endoscopy lexicon
Time frame: From the day of procedure to the completion of follow-up up to 12 months
Length of hospital stay after procedure
Time frame: From the day of procedure to discharge, assessed up to 12 months
Overall survival
Time frame: Survival rate at the end of the follow-up period, assessed up to 12 months
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →